Search Result

Results for "

TXA2 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Calcium Channel (1) Caspase (1) COX (5) Isotope-Labeled Compounds (2) Lipoxygenase (2) Na+/K+ ATPase (1) NF-κB (1) p38 MAPK (1) Prostaglandin Receptor (35) Reference Standards (5)
By Research Areas:	Cancer (8) Cardiovascular Disease (31) Endocrinology (8) Inflammation/Immunology (11) Metabolic Disease (3) Neurological Disease (6)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18763

Indobufen 2 Publications Verification Ibustrin	COX	Cardiovascular Disease
Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

HY-B0428

Ozagrel 1 Publications Verification OKY-046	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel (OKY-046) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-B0745

Ramatroban BAY u3405	Prostaglandin Receptor	Inflammation/Immunology Endocrinology Cancer
Ramatroban is a selective thromboxane A₂ (TxA₂, IC₅₀=14 nM) antagonist, which also antagonizes CRTH2 (IC₅₀=113 nM) by inhibiting PGD₂ binding.

HY-16991

Terutroban 1 Publications Verification S-18886	Prostaglandin Receptor	Cardiovascular Disease Metabolic Disease
Terutroban (S-18886) is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC₅₀ of 16.4 nM. Terutroban inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban is a potent antithrombotic agent and possesses anti-atherosclerotic and anti-vasoconstrictor properties .

HY-B0428B

Ozagrel hydrochloride 1 Publications Verification OKY-046 hydrochloride	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-B0428A

Ozagrel sodium 1 Publications Verification OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-105218A

Ifetroban sodium 1 Publications Verification BMS-180291 sodium	Prostaglandin Receptor	Cardiovascular Disease Endocrinology Cancer
Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .

HY-105218

Ifetroban 1 Publications Verification BMS-180291	Prostaglandin Receptor	Cardiovascular Disease Endocrinology Cancer
Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .

HY-B1735

Picotamide	Prostaglandin Receptor	Cardiovascular Disease
Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases .

HY-16991A

Terutroban sodium 1 Publications Verification S-18886 sodium	Prostaglandin Receptor	Cardiovascular Disease Metabolic Disease
Terutroban (S-18886) sodium is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC₅₀ of 16.4 nM. Terutroban sodium inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban sodium is a potent antithrombotic agent and possesses anti-atherosclerotic and anti-vasoconstrictor properties .

HY-135447

BM-531	Prostaglandin Receptor	Others
BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K ⁺-induced contraction of porcine uterine smooth muscle .

HY-100283

CGS 15435	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
CGS 15435, a potent thromboxane (TxA₂) synthetase inhibitor with an IC₅₀ of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI₂ synthetase and lipoxygenase enzymes.

HY-14654B

Aspirin DL-lysine Acetylsalicylic acid DL-lysine; ASA DL-lysine	COX NF-κB p38 MAPK	Cardiovascular Disease Others Inflammation/Immunology
Aspirin DL-lysine (ASA DL-lysine) is a lysine-containing aspirin derivative. Aspirin DL-lysine inhibits cyclooxygenase (COX) in platelets, blocks the synthesis of thromboxane A2 (TXA2), and thus inhibits platelet aggregation and activation. Aspirin DL-lysine can be used to study thrombin generation in patients with unstable angina pectoris .

HY-105866

Wy 27569	Calcium Channel Prostaglandin Receptor	Cardiovascular Disease
Wy 27569 is an orally active vascular selective calcium channel blocker that can effectively lower blood pressure. Wy 27569 is a thromboxane synthase inhibitor that can reshape prostaglandin balance, reduce pro thrombotic *TXA2, and increase anti thrombotic PGI2*. Wy 27569 can be used for research on cardiovascular diseases such as hypertension and angina .

HY-101606

Etersalate Eterylate; Etherylate	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Etersalate inhibits platelet function and decreases thromboxane A2 (TXA2) levels.

HY-B0428BR

Ozagrel hydrochloride (Standard) OKY-046 hydrochloride (Standard)	Reference Standards Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel hydrochloride (Standard) is the analytical reference standard of Ozagrel hydrochloride (HY-B0428B). Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-106066

Dazmegrel UK38485	Prostaglandin Receptor	Cardiovascular Disease
Dazmegrel (UK-38485) is a thromboxane synthetase inhibitor which inhibits Thromboxane A2 (TXA2) synthesis and exhibits antiplatelet vasodilator effects. Dazmegrel can be utilized in thrombosis research .

HY-18763A

Indobufen sodium Ibustrin sodium	COX	Cardiovascular Disease
Indobufen sodium is a platelet aggregation inhibitor. Indobufen sodium is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen sodium suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen sodium down-regulates tissue factor (TF) in monocytes .

HY-119890

Isbogrel CV-4151	Prostaglandin Receptor	Cardiovascular Disease Cancer
Isbogrel (CV-4151) is a potent selective inhibitor of thromboxane A2 synthase. Isbogrel has oral activity and inhibits blood TXA2 generation with an ID₅₀ value of 0.04 mg/kg .

HY-116281

ICI D1542	Prostaglandin Receptor	Cardiovascular Disease
ICI D1542 is a selective and potent inhibitor of *thromboxane A2 (TXA2) synthase* and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism .

HY-106080A

Furegrelate sodium U-63557A	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-106080

Furegrelate U-63557A free acid	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate is being developed as an antiplatelet agent .

HY-B0745S

Ramatroban-d4 BAY u3405-d₄	Isotope-Labeled Compounds Prostaglandin Receptor	Inflammation/Immunology Endocrinology Cancer
Ramatroban-d₄ is deuterium labeled Ramatroban. Ramatroban is a selective thromboxane A2 (TxA2, IC50=14 nM) antagonist, which also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding.

HY-18763S

Indobufen-d5 Ibustrin-d₅	Isotope-Labeled Compounds COX	Cardiovascular Disease
Indobufen-d₅ is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

HY-158332

Sulotroban SKF-95587; BM-13177	Prostaglandin Receptor	Cardiovascular Disease
Sulotroban (SKF-95587; BM-13177) is a selective antagonist for thromboxane A2 receptor (TXA2 Receptor). Sulotroban exhibits inhibitory activity against carbocyclic thromboxane A2- and endoperoxide-induced vasoconstrictor. Sulotroban inhibits platelets aggregation .

HY-105120

Vapiprost GR 32191	Prostaglandin Receptor	Others
Vapiprost (GR 32191) is a *thromboxane A2 receptor (TXA2* Receptor)** antagonist. Vapiprost hydrochloride (GR 32191 hydrochloride) inhibits the aggregation and ATP release stimulated with U-46619, collagen or arachidonic acid (AA) at an IC₅₀ of less than 2.1×10 ^-8 M .

HY-19166

E-6700	Lipoxygenase Prostaglandin Receptor	Inflammation/Immunology
E-6700 is an inhibitor of 5-LO and TXA2 synthetase, with IC₅₀s of 16.3 μM and 0.026 μM respectively. E-6700 inhibits LTB₄ and TXB₂ production. E-6700 can be used for antiinflammatory research .

HY-18763R

Indobufen (Standard) Ibustrin (Standard)	Reference Standards COX	Cardiovascular Disease
Indobufen (Standard) is the analytical standard of Indobufen. This product is intended for research and analytical applications. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

HY-114846

Ro 22-9194	Prostaglandin Receptor	Cardiovascular Disease
Ro 22-9194 inhibits aggregation and thromboxane Az (TXA2) synthetase activity in rabbit and human platelets. Ro 22-9194 has a potent inhibitory action against various types of model arrhythmias. Ro 22-9194 has non-cholinergic cardiac depressant properties with its vasodilating action .

HY-106080AR

Furegrelate sodium (Standard) U-63557A (Standard)	Prostaglandin Receptor Reference Standards	Cardiovascular Disease
Furegrelate (sodium) (Standard) is the analytical standard of Furegrelate (sodium). This product is intended for research and analytical applications. Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-100484

KC-764	Prostaglandin Receptor	Neurological Disease
KC-764 is an orally active, reversible cyclooxygenase inhibitor with relative selectivity for platelet cyclooxygenase. KC-764 inhibits platelet thromboxane A2 (TXA2) production and platelet aggregation, with IC₅₀s of 0.23 μM and 26 nM, respectively. KC-764 can be used for the research on antiplatelet and recurrence prevention in ischemic stroke .

HY-106105

ONO 3708	Prostaglandin Receptor	Others
ONO 3708 is a TXA₂/PGH₂ receptor antagonist that can inhibit the binding properties of U46619 in unactivated intact human platelets, with an IC₅₀ value of 38 nM .

HY-B0428D

(E/Z)-Ozagrel sodium (E/Z)-OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
(E/Z)-Ozagrel sodium [(E/Z)-OKY-046 sodium] is an EZ configuration mixture of Ozagrel sodium (HY-B0428A). Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-19064

CV-6504	Prostaglandin Receptor Lipoxygenase	Cardiovascular Disease Inflammation/Immunology Cancer
CV-6504 is a dual inhibitor of *TXA2* synthase and 5-lipoxygenase. CV-6504 can scavenge ROS and exhibit antitumor activity. CV-6504 can be used for the researches of cancer, inflammation and cardiovascular disease .

HY-B1735A

Picotamide monohydrate	Prostaglandin Receptor	Cardiovascular Disease Metabolic Disease
Picotamide monohydrate is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide monohydrate has antiplatelet activity. Picotamide monohydrate promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide monohydrate can be used for researching acute or chronic cardiovascular diseases .

HY-W169940

NP-184	Prostaglandin Receptor	Cardiovascular Disease
NP-184 is a novel orally active antithrombotic agent. NP-184 selectively inhibits TXA2 synthase activity with an IC₅₀ value of 4.3 μM. NP-184 has antiplatelet and antithrombotic activities. NP-184 can be used in the research of thromboembolic diseases .

HY-16991R

Terutroban (Standard) S-18886 (Standard)	Prostaglandin Receptor Reference Standards	Cardiovascular Disease Endocrinology
Terutroban (Standard) is the analytical standard of Terutroban. This product is intended for research and analytical applications. Terutroban (S-18886) is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC500 of 16.4 nM. Terutroban inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban is a potent antithrombotic agent and possesses antiatherosclerotic and antivasoconstrictor properties .

HY-N16733

Deacetyltanghinin	Na+/K+ ATPase Apoptosis Caspase Prostaglandin Receptor	Cancer
Deacetyltanghinin is a selective inhibitor targeting Na ⁺/K ⁺ ATPase, acting through non-covalent binding but is highly cardiotoxic. Deacetyltanghinin inhibits Na ⁺/K ⁺ ATPase activity, induces cancer cell apoptosis (involving caspase pathway activation), and at the same time affect the *TXA2*-PGI2 balance in the rabbit heart. Deacetyltanghinin has significant anti-cancer activity and is mainly used in the research field of targeted therapy of malignant tumors such as breast cancer and lung cancer. At the same time, attention should be paid to the regulation of its cardiotoxicity .

HY-105218AR

Ifetroban sodium (Standard) BMS-180291 sodium (Standard)	Reference Standards Prostaglandin Receptor	Cardiovascular Disease Endocrinology Cancer
Ifetroban sodium (Standard) is the analytical standard of Ifetroban sodium (HY-105218A). This product is intended for research and analytical applications. Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .

HY-186042

TPα/β antagonist-1	Prostaglandin Receptor	Cardiovascular Disease
TPα/β antagonist-1 is a TXA2 receptor α (TPα) and TPβ antagonist with IC₅₀s of 1.52 nM and 0.79 nM, respectively. TPα/β antagonist-1 inhibits U-46619 (HY-108566)-induced intracellular calcium mobilization, and imhibits platelet aggregation. TPα/β antagonist-1 can be used for the research of cardiovascular disease .

Cat. No.	Product Name	Type

HY-135447

BM-531	Biochemical Assay Reagents
BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K ⁺-induced contraction of porcine uterine smooth muscle .

BM-531

Biochemical Assay Reagents

BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K ⁺-induced contraction of porcine uterine smooth muscle .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N16733

Deacetyltanghinin	Apocynaceae Structural Classification Cardiacglycosides Cerbera odollam Gaertn. Plants Steroids Source Classification	Na+/K+ ATPase Apoptosis Caspase Prostaglandin Receptor
Deacetyltanghinin is a selective inhibitor targeting Na ⁺/K ⁺ ATPase, acting through non-covalent binding but is highly cardiotoxic. Deacetyltanghinin inhibits Na ⁺/K ⁺ ATPase activity, induces cancer cell apoptosis (involving caspase pathway activation), and at the same time affect the *TXA2*-PGI2 balance in the rabbit heart. Deacetyltanghinin has significant anti-cancer activity and is mainly used in the research field of targeted therapy of malignant tumors such as breast cancer and lung cancer. At the same time, attention should be paid to the regulation of its cardiotoxicity .

Cat. No.	Product Name	Chemical Structure

HY-B0745S

Ramatroban-d4
Ramatroban-d₄ is deuterium labeled Ramatroban. Ramatroban is a selective thromboxane A2 (TxA2, IC50=14 nM) antagonist, which also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding.

HY-18763S

Indobufen-d5
Indobufen-d₅ is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

TXA2 Inhibitor

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Natural
Products